Patents by Inventor James Loch

James Loch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20210214323
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: February 26, 2021
    Publication date: July 15, 2021
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin LI, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10995078
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: May 4, 2021
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • TARGETED THERAPEUTICS
    Publication number: 20210085700
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • Targeted therapeutics
    Patent number: 10828315
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: November 10, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20200347025
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: May 20, 2020
    Publication date: November 5, 2020
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10800750
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: October 13, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20200017458
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: September 10, 2019
    Publication date: January 16, 2020
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin LI, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10472342
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 12, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10457655
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 29, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10450286
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: October 22, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Compounds and compositions for inhibition of FASN
    Patent number: 10399951
    Abstract: The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 3, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20190241532
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 8, 2019
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20190241533
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 8, 2019
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20180370933
    Abstract: The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 27, 2018
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20180050997
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: October 17, 2017
    Publication date: February 22, 2018
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • TARGETED THERAPEUTICS
    Publication number: 20170056510
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: March 8, 2016
    Publication date: March 2, 2017
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20160002188
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 7, 2016
    Inventors: KENNETH W. BAIR, DAVID R. LANCIA, JR., HONGBIN LI, JAMES LOCH
  • Novel substituted amines of spirofuropyridines useful in therapy
    Publication number: 20050250802
    Abstract: Methods for the treatment of psychotic or intellectual impairment disorders with compounds of formula I, wherein A, R and R1 are as defined in the specification.
    Type: Application
    Filed: July 14, 2005
    Publication date: November 10, 2005
    Inventors: James Loch, George Mullen, Eifion Phillips